Bremazocine
Systematic (IUPAC) name | |
---|---|
6-ethyl- 3-[(1-hydroxycyclopropyl)methyl]- 11,11-dimethyl- 1,2,3,4,5,6-hexahydro- 2,6-methano- 3-benzazocin-8- ol or 2-(1-hydroxy- cyclopropylmethyl)- 5-ethyl- 9,9-dimethyl- 2'-hydroxy- 6,7-benzomorphan | |
Clinical data | |
Routes of administration | Oral |
Legal status |
|
Identifiers | |
CAS Number | 75684-07-0 |
ATC code | none |
PubChem | CID 1223 |
IUPHAR/BPS | 1603 |
ChemSpider | 1186 |
UNII | ISF76M2DBE |
ChEMBL | CHEMBL1165792 |
Chemical data | |
Formula | C20H29NO2 |
Molar mass | 315.45 g/mol |
|
Bremazocine is a κ-opioid receptor agonist related to pentazocine. It has potent and long-lasting analgesic and diuretic effects.[1] It has 200 times the activity of morphine, but appears to have no addictive properties and does not depress breathing.[2]
See also
References
- ↑ Dortch-Carnes J, Potter DE (2005). "Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties". CNS Drug Reviews 11 (2): 195–212. doi:10.1111/j.1527-3458.2005.tb00270.x. PMID 16007240.
- ↑ Patrick, Graham (2013). An Introduction to Medicinal Chemistry (5th expanded ed.). Oxford University Press. p. 641. ISBN 0199697396.
|
|
This article is issued from Wikipedia - version of the Saturday, March 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.